Clinical Research

Austin Neuromuscular Center is committed to research and clinical advancement. Our clinic is a site for clinical trials focusing mainly on neuromuscular disorders. Dr. Hussain is the principal investigator and we have an on-site trained research coordinator.

For further questions regarding enrollment or study query, please contact our research manager, Dr. Nawar Hussin, at nawar@austinneuromuscle.com or 512-920-0140 ext 6.

Clinical Trials:

  • A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM). September 2018 – Recruiting
  • A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Generalized Myasthenia Gravis. – Recruiting
  • An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis. – Recruiting
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dematomyositis. – Recruiting
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis. – Recruiting
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis. – Recruiting
  • A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis. – Pending
  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients with Sporadic Inclusion Body Myositis. September 2018 – Closed
  • A Multicenter, Double Blind, Phase 2b, Placebo Controlled Study to assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects with Amyotrophic Lather Sclerosis (ALS). June 2017 – Closed
  • Expanded Access Protocol of Patisiran for Patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) with Polyneuropathy. January 2017 – Closed
  • Patient Assisted Intervention for Neuropathy; Comparison of Treat in Real Life Situations (PAIN CONTROLS). October 2016 – Closed
  • Prospective, Double Blind, Randomized, Placebo Controlled, Phase III Study evaluating Efficacy and Safety of Octagam 10% in Patients with Dermatoymysitis. – Closed